WO2004031722A3 - Identification of a polypeptide antagonist to the peripheral-type benzodiazepine receptor (pbr) - Google Patents

Identification of a polypeptide antagonist to the peripheral-type benzodiazepine receptor (pbr) Download PDF

Info

Publication number
WO2004031722A3
WO2004031722A3 PCT/US2003/029822 US0329822W WO2004031722A3 WO 2004031722 A3 WO2004031722 A3 WO 2004031722A3 US 0329822 W US0329822 W US 0329822W WO 2004031722 A3 WO2004031722 A3 WO 2004031722A3
Authority
WO
WIPO (PCT)
Prior art keywords
pbr
identification
peripheral
benzodiazepine receptor
type benzodiazepine
Prior art date
Application number
PCT/US2003/029822
Other languages
French (fr)
Other versions
WO2004031722A2 (en
Inventor
Vassilios Papadopoulos
Maria Gazouli
Original Assignee
Univ Georgetown
Vassilios Papadopoulos
Maria Gazouli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Vassilios Papadopoulos, Maria Gazouli filed Critical Univ Georgetown
Priority to AU2003288908A priority Critical patent/AU2003288908A1/en
Publication of WO2004031722A2 publication Critical patent/WO2004031722A2/en
Publication of WO2004031722A3 publication Critical patent/WO2004031722A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the identification of an antagonist to the peripheral-type benzodiazepine receptor (PBR). The PBR is known to have a large role in many important processes of the body, such as steroid biosynthesis processes of the adrenal glands and gonads, mitochondrial respiration, apoptosis and cell proliferation. PBR is also implicated in such medical concerns as cancer progression, ischemia-reperfusion injury, Alzheimer's disease and diseases with elevated steroid levels. The present invention is directed to the use of the PBR antogonist to block receptor function to treat and prevent PBR-related diseases and conditions.
PCT/US2003/029822 2002-10-01 2003-09-23 Identification of a polypeptide antagonist to the peripheral-type benzodiazepine receptor (pbr) WO2004031722A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003288908A AU2003288908A1 (en) 2002-10-01 2003-09-23 Identification of a polypeptide antagonist to the peripheral-type benzodiazepine receptor (pbr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41463502P 2002-10-01 2002-10-01
US60/414,635 2002-10-01

Publications (2)

Publication Number Publication Date
WO2004031722A2 WO2004031722A2 (en) 2004-04-15
WO2004031722A3 true WO2004031722A3 (en) 2005-02-03

Family

ID=32069744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/029822 WO2004031722A2 (en) 2002-10-01 2003-09-23 Identification of a polypeptide antagonist to the peripheral-type benzodiazepine receptor (pbr)

Country Status (2)

Country Link
AU (1) AU2003288908A1 (en)
WO (1) WO2004031722A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055036A1 (en) * 2007-03-12 2010-03-04 National Institute of Radiolotgical Sciences Pet visualization of amyloid-associated neuroinflammation in the brain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550124A (en) * 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550124A (en) * 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAZOULI ET AL.: "Identification of a Peptide Antogonist to the Peripheral-Type Benzodiazepine Receptor", J. PHARMACOLOGY AND EXP. THERAPEUTICS, vol. 303, November 2002 (2002-11-01), pages 627 - 632, XP002983880 *

Also Published As

Publication number Publication date
AU2003288908A1 (en) 2004-04-23
AU2003288908A8 (en) 2004-04-23
WO2004031722A2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
AU7031500A (en) Therapeutic quinazoline compounds
HUP0000558A2 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
HK1123741A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine)
IL214607A (en) 2,4-pyrimidinediamine compounds and their use in the manufacture of medicaments for the treatment of autoimmune diseases
NZ544472A (en) Compounds and therapeutical use thereof
EP1539234A4 (en) Methods of preventing or treating cell malignancies by administering cd2 antagonists
EP1178988A4 (en) Compounds and therapeutic methods
ZA200203431B (en) Therapeutic use.
EP1663104A4 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
PT1390371E (en) OXAZOLO- AND FUROPYRIMIDINES AND THEIR USE IN MEDICINES AGAINST TUMORS
DE60324431D1 (en) DERIVATIVES OF 3-HYDROXY-4- (CYCLYL-ALKYLAMINOALKYL) -5-PHENYL-1H-PYRAZOLE AS ANTAGONISTS OF GONADOTROPINE RELEASING HORMONE (GNRH) FOR THE USE OF THE TREATMENT OF HEALTH HORMONAL DISEASES SUCH AS PROSTATE OR CANCER CANCER
PL375527A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
IL156777A0 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
AU2002357644A8 (en) Therapeutic agents and corresponding treatments
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
WO2004031722A3 (en) Identification of a polypeptide antagonist to the peripheral-type benzodiazepine receptor (pbr)
NZ512289A (en) Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor
HK1038510B (en) Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP